| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[2] Salbutamol nebulisation: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. http://www.ginasthma.org/
Salbutamol nebulisation: British Thoracic Society. Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma, October 2014. Available at: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/
Salbutamol nebulisation: Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev. 2003;(4):CD001115. http://www.ncbi.nlm.nih.gov/pubmed/14583926
Salbutamol nebulisation: South African Medicines Formulary. 12th Edition. Division of Clinical Pharmacology. University of Cape Town. 2016.